ClinicalTrials.gg
CompletedNCT04687072ADVANCE SCUpdated Oct 31, 2024Results posted

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

A Phase 3 interventional study of Efgartigimod PH20 SC and Placebo PH20 SC in Primary Immune Thrombocytopenia, sponsored by argenx. Completed at 200 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan — 6 open to participants now, 10 under way, 7 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Japan.

Enrollment
3rd of 21
207 · median 105
Started
2020
with 4 others
Phase 3
16 of 23
2 open now
Registered
12th of 23
by date
Lead sponsor
5 of 23
argenx

Among the 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2020, is one of 16 in phase 3, and was the 12th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan, or all of them as a file.
02

Study summary

This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.

03

Conditions studied

  • Primary Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand the requirements of the trial and provide written , willing and able to comply with the trial protocol procedures
  • Is at least the local age of consent for clinical studies when signing the ICF.
  • Confirmed diagnosis of primary ITP made at least 3 months before randomization and based on the American Society of Hematology Criteria, and no known etiology for thrombocytopenia
  • Diagnosis supported by a response to a prior ITP therapy (other than TPO-RAs), in the opinion of the investigator
  • Mean count of \<30×10E9/L from at least 3 documented, qualifying counts within the 3 preceding months where at least 2 of the qualifying counts must be taken during the screening period: 1 platelet count collected during the screening period and the predose platelet count on the day of randomization (visit 1). If the third count is not available from the 3 preceding months, this third platelet count can be obtained during the screening period.
  • A documented history of a platelet count of \<30×10E9/L before screening
  • At the start of the trial, the participant either takes concurrent ITP treatment(s) and has received at least 1 prior therapy for ITP in the past, or the participant does not take treatment for ITP (see note) but has received at least 2 prior treatments for ITP. Participants receiving permitted concurrent ITP treatment(s) at baseline must have been stable in dose and frequency for at least 4 weeks before randomization.

Permitted concurrent ITP medications include , danazol, vinca alkaloids, oral , dapsone, fostamatinib, and/or oral TPO-RAs.

-Agree to use measures consistent with local regulations and the protocol

Exclusion criteria

Exclusion criteria:

  • Secondary ITP/thrombocytopenia associated with another condition, eg, lymphoma, chronic lymphocytic leukemia, viral infection, hepatitis, induced or alloimmune thrombocytopenia, thrombocytopenia associated with myeloid dysplasia, or hematopoietic stem cell transplant
  • Use of anticoagulants (eg, vitamin K antagonists, direct oral anticoagulants) within 4 weeks prior to randomization
  • Use of any transfusions within 4 weeks prior to randomization
  • Use of Ig (IV, SC, or intramuscular route) or plasmapheresis (PLEX) within 4 weeks prior to randomization
  • Use of romiplostim within 4 weeks prior to randomization
  • Undergone splenectomy less than 4 weeks prior to randomization
  • Use of an product within 3 months or 5 half-lives (whichever is longer) before the first dose of the IMP
  • Use of any monoclonal antibody or Fc fusion proteins, other than those previously indicated, within 6 months before the first dose of the IMP (eg, anti-CD20)
  • At the screening visit, laboratory abnormalities as follows: ≤9 g/dL - OR - >1.5 or activated partial thromboplastin time >1.5× - OR - total IgG level \<6 g/L
  • History of unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before the first administration of IMP. Participants with the following cancer can be included at any time: Adequately treated basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast or Incidental histological finding of prostate cancer (TNM stage T1a or T1b)
  • Uncontrolled hypertension, defined as a repeated elevated blood pressure exceeding 160 mmHg (systolic) and/or 100 mmHg (diastolic) despite appropriate treatments
  • History of any major thrombotic or embolic event (eg, myocardial infarction, stroke, deep venous thrombosis, or pulmonary embolism) within 5 years prior to randomization
  • History of coagulopathy or hereditary thrombocytopenia or a family history of thrombocytopenia
  • Evidence of an active clinically significant bleeding of an organ or internal mucosal bleeding, other than expected in ITP, that warrants emergent treatment or therapeutic procedure based on the investigator's judgment (eg, intracranial hemorrhage, pulmonary hemorrhage, bleeding with ongoing need for packed red blood cell transfusion)
  • Estimated high risk of a clinically significant bleeding of an organ or internal mucosal bleeding, other than expected in ITP, that warrants emergent treatment or therapeutic procedure according to the investigator's judgment
  • Clinical evidence of other significant serious diseases, have had a recent major surgery, or who have any other condition in the opinion of the investigator, that could confound the results of the trial or put the participant at undue risk
  • Positive serum test at screening for an active viral infection with any of the following conditions: virus (HBV) that is indicative of an acute or chronic infection, unless associated with a negative HBV DNA test, virus (HCV) based on HCV-antibody assay (unless associated with a negative HCV RNA test), (HIV) based on test results that are associated with an acquired immunodeficiency syndrome (AIDS)-defining condition or a ≤200 cells/mm3
  • Known reaction to efgartigimod, rHuPH20, or 1 of its
  • Previously participated in a clinical trial with efgartigimod and have received at least 1 administration of the IMP
  • Pregnant or lactating or intends to become pregnant during the trial
  • Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening
  • Any other known disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of ITP or put the participant at undue risk
  • Clinical evidence of significant unstable or uncontrolled acute or chronic diseases other than ITP (eg, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrine, hepatic, renal, neurological, malignancy, infectious diseases, uncontrolled diabetes) despite appropriate treatments which could put the participant at undue risk
  • Current or history of (ie, within 12 months of screening) alcohol, drug, or medication abuse
  • Received a live/ less than 4 weeks before screening. The receipt of any inactivated, sub-unit, polysaccharide, or conjugate vaccine at any time before screening is not considered an exclusion criterion
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Efgartigimod PH20 SC

    Patients receiving efgartigimod PH20 SC treatment

    Biological: Efgartigimod PH20 SC

  • Placebo comparator
    Placebo PH20 SC

    Patients receiving placebo PH20 SC treatment

    Other: Placebo PH20 SC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24

    A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 of the 6 analysis visits between Weeks 19 and 24.

    Time frame: Up to 6 weeks (between Weeks 19 and 24)

Secondary outcomes

  1. Extent of Disease Control Over the 24-Week Treatment Period in the Chronic ITP Population

    Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥50×10\^9/L in the chronic ITP population.

    Time frame: Up to 24 weeks

  2. Percentage of Participants in the Overall Population (Chronic and Persistent ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24

    A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 of the 6 analysis visits between Weeks 19 and 24.

    Time frame: Up to 6 weeks (between Weeks 19 and 24)

  3. Percentage of Participants in the Overall Population With Sustained Platelet Count Response Between Weeks 17 and 24

    A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥6 of the 8 analysis visits between weeks 17 and 24.

    Time frame: Up to 8 weeks (between Weeks 17 and 24)

  4. Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time During the 24-week Treatment Period

    A participant was considered a responder for this endpoint (i.e., had an overall platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 analysis visits at any time during the 24-week treatment period.

    Time frame: Up to 24 weeks

  5. Extent of Disease Control Until Week 12 in the Overall Population

    Extent of disease control was defined as the number of cumulative weeks until Week 12 with platelet counts of ≥50×10\^9/L in the overall population.

    Time frame: Up to 12 weeks

  6. Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time Until Week 12

    A participant was considered a responder for this endpoint (i.e., had an overall platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 analysis visits at any time until Week 12.

    Time frame: Up to 12 weeks

  7. Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population

    Change from Baseline at time point t = value at time point t - Baseline value. Baseline was defined as the last available value prior to first administration of the investigational medicinal product (IMP).

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, Safety and Efficacy Follow-up Visit 1 (SEFU1) (up to Week 29), and SEFU2 (up to Week 33)

  8. Time to Platelet Count Response in the Overall Population

    Time to platelet count response, defined as the time to have 2 consecutive platelet counts of ≥50 × 10\^9/L via Kaplan-Meier estimates.

    Time frame: Up to 24 weeks

  9. Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population

    Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10\^9/L with at least ≥20×10\^9/L above Baseline in the overall population.

    Time frame: Up to 24 weeks

  10. Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population for Participants With Baseline Platelet Count of <15×10^9/L

    Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10\^9/L with at least ≥20×10\^9/L above Baseline in the overall population.

    Time frame: Up to 24 weeks

  11. Number of the World Health Organization (WHO)-Classified Bleeding Events (Grade ≥1) in the Overall Population

    Assessed using the WHO bleeding scale. The WHO bleeding scale is a five-point scale where Grade 0 = no bleeding; Grade 1 = petechial bleeding; Grade 2 = mild blood loss; Grade 3 = gross blood loss (requires transfusion); and Grade 4 = debilitating blood loss, associated with fatality.

    Time frame: Up to 24 weeks

  12. Percentage of Participants With a Platelet Count International Working Group (IWG) Response

    IWG complete response was defined as platelet counts of ≥100 × 10\^9/L and the absence of bleeding events (WHO Grading = 0 \[no bleeding\]) for at least 2 separate, consecutive analysis visits at least 7 days apart. IWG response was defined as platelet counts of ≥30 × 10\^9/L and a 2-fold increase of platelet count from Baseline and the absence of bleeding events (WHO grading = 0) for at least 2 separate, consecutive analysis visits that were at least 7 days apart. Initial response was defined as platelet counts of ≥30 × 10\^9/L and a 2-fold increase from the Baseline platelet count at analysis visit 5.

    Time frame: Up to 24 weeks

  13. Rate of Receipt of Rescue Therapy (Rescue Per Participant Per Month) in the Overall Population

    Rescue therapy was defined as an occurrence where the participant needed treatment with 1 or more rescue treatments. An occurrence was defined as a period of maximum 5 days where 1 or more rescue treatments were administered simultaneously or consecutively to the trial participant. The following rescue treatments were permitted: methylprednisolone, dexamethasone, prednisone, normal immunoglobulins, anti-D (Rho) immunoglobins, or platelet transfusions.

    Time frame: Up to 24 weeks

  14. Percentage of Participants for Whom Dose and/or Frequency of Concurrent ITP Therapies Have Increased at Week 12 or Later in the Overall Population

    A change in ITP therapy was defined as either an increase in the dose and/or frequency of a concurrent ITP therapy relative to Baseline or the initiation of a new concurrent ITP therapy.

    Time frame: Up to 13 weeks (between Weeks 12 and 24)

  15. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 24 in the Overall Population

    The FACIT-fatigue scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during his/her usual daily activities over the past week. The level of fatigue was measured by recording item responses on a 5-point Likert scale ranging from 0 "not at all" to 4 "very much". All items were summed to create a single fatigue score with a range from 0 to 52, where a higher FACIT-F score indicated more severe symptoms. A negative change score from Baseline indicated improvement in quality of life (QoL).

    Time frame: Baseline and Week 24

  16. Change From Baseline in Functional Assessment of Cancer Therapy Questionnaire-Th6 (Fact-Th6) at Week 24 in the Overall Population

    The FACT-Th6 uses a 5-level Likert scale (0=not at all to 4=very much), with participants rating their degree of concern in the past 7 days. The 6 selected items pertain to ability to do usual activities, worry about problems with bleeding or bruising, worry about the possibility of serious bleeding, avoidance of physical or social activity because of concern with bleeding or bruising and frustration due to the inability to carry out usual activities. All items were summed to create a single score with a range from 0 to 24, where a higher score indicated less severe symptoms. A positive change score from Baseline indicated improvement in QoL.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24

  17. Change From Baseline in Short Form-36 (SF-36) at Week 24 in the Overall Population

    The SF-36 is a 36-item scale constructed to survey health-related QoL on 8 domains: limitations in physical activities due to health problems; limitations in social activities due to physical or emotional problems; limitations in usual role activities due to physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities due to emotional problems; vitality (energy and fatigue); and general health perceptions. The scores from the 8 domains were evaluated independently and aggregated into 2 norm-based summary component measures of physical and mental health. The summary component scores could range from 0 to 100, where a higher score indicated improvement in QoL. A positive change score from Baseline indicated improvement in QoL.

    Time frame: Baseline and Week 24

  18. Incidence and Prevalence of Antibodies to Efgartigimod and/or rHuPH20 in the Overall Population

    Anti-drug antibody (ADA) incidence was defined as the percentage of participants with treatment-induced or treatment boosted ADA (denominator: number of evaluable participants). ADA prevalence was defined as the percentage of participants with treatment-unaffected ADA, treatment-induced ADA or treatment-boosted ADA (denominator: number of evaluable participants).

    Time frame: Up to 35 weeks

  19. Titers of Antibodies to Efgartigimod and/or rHuPH20 in the Overall Population

    A titer was determined in the samples with a positive assay response.

    Time frame: Weeks 3, 7, 11, 15, 19, 23, 24, SEFU1 (up to Week 29), and SEFU2 (up to Week 33)

  20. Incidence and Prevalence of Neutralizing Antibodies (NAb) to Efgartigimod and/or rHuPH20 in the Overall Population

    Samples were tested for the presence of NAb against efgartigimod and/or rHuPH20 and titers for NAb against rHuPH20. NAb incidence is defined as the total percentage of participants with participant classification "baseline negative-postbaseline positive" and "baseline positive-postbaseline positive". NAb prevalence is defined as the total percentage of participants with participant classification "baseline negative-postbaseline positive," "baseline positive-postbaseline positive," or "baseline positive-postbaseline negative".

    Time frame: Up to 35 weeks

  21. Serum Efgartigimod Trough Concentration (Ctrough) in the Overall Population

    All pharmacokinetic (PK) samples were collected predose, on the day of IMP administration.

    Time frame: Predose on Weeks 1, 2, 3, 17, 19, 21, 23, and 24

  22. Percentage Change From Baseline in Total IgG in the Overall Population

    Samples were collected predose, on the day of IMP administration.

    Time frame: Baseline and Weeks 1, 2, 3, 17, 19, 21, 23, and 24

  23. Number of Participants With Antiplatelet Antibodies in the Overall Population

    The antiplatelet antibody was positive if optical density value \>0.129.

    Time frame: Weeks 7, 15, 23, and 24

07

Results

Posted Oct 31, 2024

Participant flow

A regionally diverse participant population was enrolled (including but not limited to North America, East Asia, Europe, and the rest of world \[ROW\]). A total of 207 participants were randomized to IMP: 137 participants in the efgartigimod PH20 subcutaneous (SC) arm and 70 participants in the placebo PH20 SC arm.

Participant flow — Overall Study
MilestoneEfgartigimod PH20 SCPlacebo PH20 SC
Started13770
Completed11362
Not completed248
Withdrew: Adverse event20
Withdrew: Death10
Withdrew: Lack of efficacy21
Withdrew: Physician decision10
Withdrew: Pregnancy10
Withdrew: Requires prohibited medication20
Withdrew: Withdrawal of consent116
Withdrew: Miscellaneous41

Outcome measures

PrimaryPercentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24

A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 of the 6 analysis visits between Weeks 19 and 24.

Time frame:
Up to 6 weeks (between Weeks 19 and 24)
Reported as:
Number · percentage of participants
Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 2413.716.2
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Cochran-Mantel-Haenszel · p = 0.5081 (The p-value was calculated using the Cochran-Mantel-Haenszel test used in the hierarchical testing procedure.) · Difference in percentage: -3.5 · 95% CI -14.7 to 7.0The adjusted difference in percentages and 95% confidence interval (CI) (Klingenberg approach) were presented.
SecondaryExtent of Disease Control Over the 24-Week Treatment Period in the Chronic ITP Population

Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥50×10\^9/L in the chronic ITP population.

Time frame:
Up to 24 weeks
Reported as:
Median · weeks
Extent of Disease Control Over the 24-Week Treatment Period in the Chronic ITP Population
weeksEfgartigimod PH20 SCPlacebo PH20 SC
Extent of Disease Control Over the 24-Week Treatment Period in the Chronic ITP Population0.5 (0 to 24)0.0 (0 to 23)
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Wilcoxon (Mann-Whitney) · p = 0.4925 (The p-value was calculated using the stratified Mann-Whitney test used in the hierarchical testing procedure.) · Location shift: 0.000 · 95% CI 0.000 to 0.000The Hodges-Lehmann estimator of the treatment difference and 95% CI are presented.
SecondaryPercentage of Participants in the Overall Population (Chronic and Persistent ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24

A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 of the 6 analysis visits between Weeks 19 and 24.

Time frame:
Up to 6 weeks (between Weeks 19 and 24)
Reported as:
Number · percentage of participants
Percentage of Participants in the Overall Population (Chronic and Persistent ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
Percentage of Participants in the Overall Population (Chronic and Persistent ITP) With a Sustained Platelet Count Response Between Weeks 19 and 2416.115.7
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Cochran-Mantel-Haenszel · p = 0.9314 (The p-value was calculated using the Cochran-Mantel-Haenszel test used in the hierarchical testing procedure.) · Difference in percentage: -0.5 · 95% CI -11.7 to 10.0The adjusted difference in percentages and 95% CI (Klingenberg approach) were presented.
SecondaryPercentage of Participants in the Overall Population With Sustained Platelet Count Response Between Weeks 17 and 24

A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥6 of the 8 analysis visits between weeks 17 and 24.

Time frame:
Up to 8 weeks (between Weeks 17 and 24)
Reported as:
Number · percentage of participants
Percentage of Participants in the Overall Population With Sustained Platelet Count Response Between Weeks 17 and 24
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
Percentage of Participants in the Overall Population With Sustained Platelet Count Response Between Weeks 17 and 2412.414.3
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Cochran-Mantel-Haenszel · p = 0.7379 (The Cochran-Mantel-Haenszel test p-value was used in the hierarchical testing procedure.) · Difference in percentage: -1.7 · 95% CI -12.4 to 8.2The adjusted difference in percentage and 95% CI (Klingenberg approach) are presented.
SecondaryPercentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time During the 24-week Treatment Period

A participant was considered a responder for this endpoint (i.e., had an overall platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 analysis visits at any time during the 24-week treatment period.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time During the 24-week Treatment Period
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time During the 24-week Treatment Period29.925.7
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Difference in percentage: 4.2 · 95% CI -9.3 to 16.8
SecondaryExtent of Disease Control Until Week 12 in the Overall Population

Extent of disease control was defined as the number of cumulative weeks until Week 12 with platelet counts of ≥50×10\^9/L in the overall population.

Time frame:
Up to 12 weeks
Reported as:
Median · weeks
Extent of Disease Control Until Week 12 in the Overall Population
weeksEfgartigimod PH20 SCPlacebo PH20 SC
Extent of Disease Control Until Week 12 in the Overall Population0.00 (0.00 to 12.00)0.00 (0.00 to 11.00)
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Wilcoxon (Mann-Whitney) · p = 0.7260 (The p-value was calculated using the stratified Mann-Whitney test.) · Location shift: 0.000 · 95% CI 0.000 to 0.000The Hodges-Lehmann estimator of the treatment difference and 95% CI are presented.
SecondaryPercentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time Until Week 12

A participant was considered a responder for this endpoint (i.e., had an overall platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 analysis visits at any time until Week 12.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time Until Week 12
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time Until Week 1218.215.7
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Difference in percentage: 2.5 · 95% CI -9.6 to 13.0The 95% Agresti-Min CIs are presented.
SecondaryMean Change From Baseline in Platelet Count at Each Visit in the Overall Population

Change from Baseline at time point t = value at time point t - Baseline value. Baseline was defined as the last available value prior to first administration of the investigational medicinal product (IMP).

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, Safety and Efficacy Follow-up Visit 1 (SEFU1) (up to Week 29), and SEFU2 (up to Week 33)
Reported as:
Mean · platelets x10^9/L
Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population
platelets x10^9/LEfgartigimod PH20 SCPlacebo PH20 SC
Week 113.84 ± 41.1508.82 ± 34.355
Week 216.62 ± 49.40823.54 ± 85.005
Week 317.07 ± 39.85519.22 ± 71.947
Week 412.39 ± 37.8869.31 ± 26.813
Week 518.14 ± 54.33512.24 ± 30.059
Week 634.61 ± 112.20416.35 ± 40.891
Week 728.25 ± 107.93213.46 ± 41.876
Week 821.77 ± 52.30816.57 ± 42.508
Week 919.90 ± 54.54220.42 ± 53.488
Week 1021.73 ± 47.68515.42 ± 33.119
Week 1120.13 ± 42.19314.54 ± 25.588
Week 1221.02 ± 43.88222.28 ± 56.173
Week 1322.29 ± 44.65415.51 ± 37.651
Week 1423.60 ± 47.52124.04 ± 55.678
Week 1521.30 ± 45.77628.05 ± 67.897
Week 1630.32 ± 71.55323.09 ± 46.154
Week 1725.12 ± 54.74730.05 ± 56.581
Week 1828.54 ± 53.11531.64 ± 57.309
Week 1933.86 ± 59.32337.26 ± 68.832
Week 2030.87 ± 55.34225.85 ± 48.409
Week 2130.04 ± 61.43826.23 ± 50.323
Week 2233.26 ± 61.55829.23 ± 55.175
Week 2329.51 ± 53.43724.89 ± 41.103
Week 2425.51 ± 52.20324.91 ± 42.972
SEFU140.44 ± 64.86048.70 ± NA
SEFU230.00 ± 35.01156.25 ± 85.206
SecondaryTime to Platelet Count Response in the Overall Population

Time to platelet count response, defined as the time to have 2 consecutive platelet counts of ≥50 × 10\^9/L via Kaplan-Meier estimates.

Time frame:
Up to 24 weeks
Reported as:
Median · days
Time to Platelet Count Response in the Overall Population
daysEfgartigimod PH20 SCPlacebo PH20 SC
Time to Platelet Count Response in the Overall PopulationNA (155.0 to NA)NA (NA to NA)
SecondaryExtent of Disease Control Over the 24-Week Treatment Period in the Overall Population

Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10\^9/L with at least ≥20×10\^9/L above Baseline in the overall population.

Time frame:
Up to 24 weeks
Reported as:
Median · weeks
Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population
weeksEfgartigimod PH20 SCPlacebo PH20 SC
Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population1.0 (0 to 24)1.0 (0 to 24)
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Wilcoxon (Mann-Whitney) · p = 0.2929 (The p-value was calculated using the stratified Mann-Whitney test.) · Location shift: 0.000 · 95% CI 0.000 to 1.000The Hodges-Lehmann estimator of the treatment difference and 95% CI are presented.
SecondaryExtent of Disease Control Over the 24-Week Treatment Period in the Overall Population for Participants With Baseline Platelet Count of <15×10^9/L

Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10\^9/L with at least ≥20×10\^9/L above Baseline in the overall population.

Time frame:
Up to 24 weeks
Reported as:
Median · weeks
Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population for Participants With Baseline Platelet Count of <15×10^9/L
weeksEfgartigimod PH20 SCPlacebo PH20 SC
Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population for Participants With Baseline Platelet Count of <15×10^9/L1.0 (0 to 23)0.0 (0.0 to 24)
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Wilcoxon (Mann-Whitney) · p = 0.1475 (The p-value was calculated using the stratified Mann-Whitney test.) · Location shift: 0.000 · 95% CI 0.000 to 1.000The Hodges-Lehmann estimator of the treatment difference and 95% CI are presented.
SecondaryNumber of the World Health Organization (WHO)-Classified Bleeding Events (Grade ≥1) in the Overall Population

Assessed using the WHO bleeding scale. The WHO bleeding scale is a five-point scale where Grade 0 = no bleeding; Grade 1 = petechial bleeding; Grade 2 = mild blood loss; Grade 3 = gross blood loss (requires transfusion); and Grade 4 = debilitating blood loss, associated with fatality.

Time frame:
Up to 24 weeks
Reported as:
Median · bleeding events
Number of the World Health Organization (WHO)-Classified Bleeding Events (Grade ≥1) in the Overall Population
bleeding eventsEfgartigimod PH20 SCPlacebo PH20 SC
Number of the World Health Organization (WHO)-Classified Bleeding Events (Grade ≥1) in the Overall Population9.0 (0 to 24)10.0 (0 to 24)
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Wilcoxon (Mann-Whitney) · p = 0.7677 (The p-value was calculated using the stratified Mann-Whitney test used in the hierarchical testing procedure.) · Location shift: 0.000 · 95% CI -2.000 to 2.000The Hodges-Lehmann estimator of the treatment difference and 95% CI are presented.
SecondaryPercentage of Participants With a Platelet Count International Working Group (IWG) Response

IWG complete response was defined as platelet counts of ≥100 × 10\^9/L and the absence of bleeding events (WHO Grading = 0 \[no bleeding\]) for at least 2 separate, consecutive analysis visits at least 7 days apart. IWG response was defined as platelet counts of ≥30 × 10\^9/L and a 2-fold increase of platelet count from Baseline and the absence of bleeding events (WHO grading = 0) for at least 2 separate, consecutive analysis visits that were at least 7 days apart. Initial response was defined as platelet counts of ≥30 × 10\^9/L and a 2-fold increase from the Baseline platelet count at analysis visit 5.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Platelet Count International Working Group (IWG) Response
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
IWG Complete Response10.211.4
IWG Response28.520.0
Initial Response19.717.1
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Difference in percentage: -1.2 · 95% CI -11.8 to 7.3The 95% Agresti-Min CIs are presented.
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Difference in percentage: 8.5 · 95% CI -4.6 to 20.2The 95% Agresti-Min CIs are presented.
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Difference in percentage: 2.6 · 95% CI -9.7 to 13.3The 95% Agresti-Min CIs are presented.
SecondaryRate of Receipt of Rescue Therapy (Rescue Per Participant Per Month) in the Overall Population

Rescue therapy was defined as an occurrence where the participant needed treatment with 1 or more rescue treatments. An occurrence was defined as a period of maximum 5 days where 1 or more rescue treatments were administered simultaneously or consecutively to the trial participant. The following rescue treatments were permitted: methylprednisolone, dexamethasone, prednisone, normal immunoglobulins, anti-D (Rho) immunoglobins, or platelet transfusions.

Time frame:
Up to 24 weeks
Reported as:
Mean · rescues per participant per month
Rate of Receipt of Rescue Therapy (Rescue Per Participant Per Month) in the Overall Population
rescues per participant per monthEfgartigimod PH20 SCPlacebo PH20 SC
Rate of Receipt of Rescue Therapy (Rescue Per Participant Per Month) in the Overall Population0.25 ± 0.5530.17 ± 0.363
SecondaryPercentage of Participants for Whom Dose and/or Frequency of Concurrent ITP Therapies Have Increased at Week 12 or Later in the Overall Population

A change in ITP therapy was defined as either an increase in the dose and/or frequency of a concurrent ITP therapy relative to Baseline or the initiation of a new concurrent ITP therapy.

Time frame:
Up to 13 weeks (between Weeks 12 and 24)
Reported as:
Number · percentage of participants
Percentage of Participants for Whom Dose and/or Frequency of Concurrent ITP Therapies Have Increased at Week 12 or Later in the Overall Population
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
Percentage of Participants for Whom Dose and/or Frequency of Concurrent ITP Therapies Have Increased at Week 12 or Later in the Overall Population11.715.7
Statistical analysis
  • Efgartigimod PH20 SC vs Placebo PH20 SC · Difference in percentage: -4.0 · 95% CI -15.6 to 5.7The 95% Agresti-Min CIs are presented.
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 24 in the Overall Population

The FACIT-fatigue scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during his/her usual daily activities over the past week. The level of fatigue was measured by recording item responses on a 5-point Likert scale ranging from 0 "not at all" to 4 "very much". All items were summed to create a single fatigue score with a range from 0 to 52, where a higher FACIT-F score indicated more severe symptoms. A negative change score from Baseline indicated improvement in quality of life (QoL).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 24 in the Overall Population
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 24 in the Overall Population-0.025 ± 0.7120.741 ± 0.985
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy Questionnaire-Th6 (Fact-Th6) at Week 24 in the Overall Population

The FACT-Th6 uses a 5-level Likert scale (0=not at all to 4=very much), with participants rating their degree of concern in the past 7 days. The 6 selected items pertain to ability to do usual activities, worry about problems with bleeding or bruising, worry about the possibility of serious bleeding, avoidance of physical or social activity because of concern with bleeding or bruising and frustration due to the inability to carry out usual activities. All items were summed to create a single score with a range from 0 to 24, where a higher score indicated less severe symptoms. A positive change score from Baseline indicated improvement in QoL.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Functional Assessment of Cancer Therapy Questionnaire-Th6 (Fact-Th6) at Week 24 in the Overall Population
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
Change From Baseline in Functional Assessment of Cancer Therapy Questionnaire-Th6 (Fact-Th6) at Week 24 in the Overall Population0.225 ± 0.3600.359 ± 0.498
SecondaryChange From Baseline in Short Form-36 (SF-36) at Week 24 in the Overall Population

The SF-36 is a 36-item scale constructed to survey health-related QoL on 8 domains: limitations in physical activities due to health problems; limitations in social activities due to physical or emotional problems; limitations in usual role activities due to physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities due to emotional problems; vitality (energy and fatigue); and general health perceptions. The scores from the 8 domains were evaluated independently and aggregated into 2 norm-based summary component measures of physical and mental health. The summary component scores could range from 0 to 100, where a higher score indicated improvement in QoL. A positive change score from Baseline indicated improvement in QoL.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Short Form-36 (SF-36) at Week 24 in the Overall Population
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
Week 24: Mental Component1.215 ± 0.6200.957 ± 0.841
Week 24: Physical Component-0.848 ± 0.525-0.850 ± 0.712
SecondaryIncidence and Prevalence of Antibodies to Efgartigimod and/or rHuPH20 in the Overall Population

Anti-drug antibody (ADA) incidence was defined as the percentage of participants with treatment-induced or treatment boosted ADA (denominator: number of evaluable participants). ADA prevalence was defined as the percentage of participants with treatment-unaffected ADA, treatment-induced ADA or treatment-boosted ADA (denominator: number of evaluable participants).

Time frame:
Up to 35 weeks
Reported as:
Number · percentage of participants
Incidence and Prevalence of Antibodies to Efgartigimod and/or rHuPH20 in the Overall Population
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
Incidence of Antibodies to Efgartigimod5.12.9
Prevalence of Antibodies to Efgartigimod16.27.1
Incidence of Antibodies to rHuPH2041.220.0
Prevalence of Antibodies to rHuPH2050.031.4
SecondaryTiters of Antibodies to Efgartigimod and/or rHuPH20 in the Overall Population

A titer was determined in the samples with a positive assay response.

Time frame:
Weeks 3, 7, 11, 15, 19, 23, 24, SEFU1 (up to Week 29), and SEFU2 (up to Week 33)
Reported as:
Mean · titer
Titers of Antibodies to Efgartigimod and/or rHuPH20 in the Overall Population
titerEfgartigimod PH20 SCPlacebo PH20 SC
Week 3: ADA Against Efgartigimod Titer—16.5 ± 15.50
Week 7: ADA Against Efgartigimod Titer1.0 ± NA11.3 ± 10.33
Week 11: ADA Against Efgartigimod Titer—6.3 ± 4.84
Week 15: ADA Against Efgartigimod Titer—8.5 ± 7.50
Week 23: ADA Against Efgartigimod Titer—2.0 ± NA
Week 24: ADA Against Efgartigimod Titer16.3 ± 8.951.0 ± 0.00
SEFU1: ADA Against Efgartigimod Titer2.5 ± 1.50—
SEFU2: ADA Against Efgartigimod Titer17.0 ± 15.00—
Week 3: ADA Against rHuPH20 Titer12.7 ± 2.5314.1 ± 3.15
Week 7: ADA Against rHuPH20 Titer645.9 ± 314.7914.4 ± 4.27
Week 11: ADA Against rHuPH20 Titer2204.8 ± 1297.4311.4 ± 2.37
Week 15: ADA Against rHuPH20 Titer3209.3 ± 1325.9615.7 ± 2.02
Week 19: ADA Against rHuPH20 Titer3742.7 ± 1414.1549.1 ± 27.87
Week 23: ADA Against rHuPH20 Titer5936.6 ± 2180.3358.3 ± 27.83
Week 24: ADA Against rHuPH20 Titer4731.3 ± 1898.9669.1 ± 26.60
SEFU1: ADA Against rHuPH20 Titer5122.5 ± 5117.50—
SEFU2: ADA Against rHuPH20 Titer5160.0 ± 5080.00—
SecondaryIncidence and Prevalence of Neutralizing Antibodies (NAb) to Efgartigimod and/or rHuPH20 in the Overall Population

Samples were tested for the presence of NAb against efgartigimod and/or rHuPH20 and titers for NAb against rHuPH20. NAb incidence is defined as the total percentage of participants with participant classification "baseline negative-postbaseline positive" and "baseline positive-postbaseline positive". NAb prevalence is defined as the total percentage of participants with participant classification "baseline negative-postbaseline positive," "baseline positive-postbaseline positive," or "baseline positive-postbaseline negative".

Time frame:
Up to 35 weeks
Reported as:
Number · percentage of participants
Incidence and Prevalence of Neutralizing Antibodies (NAb) to Efgartigimod and/or rHuPH20 in the Overall Population
percentage of participantsEfgartigimod PH20 SCPlacebo PH20 SC
Incidence of NAb to Efgartigimod0.70.0
Prevalence of NAb to Efgartigimod5.10.0
Incidence of NAb to rHuPH200.00.0
Prevalence of NAb to rHuPH200.00.0
SecondarySerum Efgartigimod Trough Concentration (Ctrough) in the Overall Population

All pharmacokinetic (PK) samples were collected predose, on the day of IMP administration.

Time frame:
Predose on Weeks 1, 2, 3, 17, 19, 21, 23, and 24
Reported as:
Mean · μg/mL
Serum Efgartigimod Trough Concentration (Ctrough) in the Overall Population
μg/mLEfgartigimod PH20 SC
Week 113.2 ± 6.46
Week 216.6 ± 8.17
Week 317.0 ± 7.95
Week 1715.1 ± 8.54
Week 1915.4 ± 7.43
Week 2115.1 ± 8.86
Week 2314.9 ± 7.79
Week 2414.7 ± 8.10
SecondaryPercentage Change From Baseline in Total IgG in the Overall Population

Samples were collected predose, on the day of IMP administration.

Time frame:
Baseline and Weeks 1, 2, 3, 17, 19, 21, 23, and 24
Reported as:
Mean · percentage of total IgG
Percentage Change From Baseline in Total IgG in the Overall Population
percentage of total IgGEfgartigimod PH20 SCPlacebo PH20 SC
Week 1-33.64 ± 26.0180.60 ± 14.065
Week 2-50.68 ± 34.97310.31 ± 44.858
Week 3-56.80 ± 39.1334.97 ± 28.484
Week 17-64.76 ± 11.4781.27 ± 16.749
Week 19-60.98 ± 26.4609.28 ± 44.989
Week 21-62.38 ± 15.1764.62 ± 25.406
Week 23-62.45 ± 20.2862.45 ± 21.271
Week 24-61.97 ± 18.200-0.36 ± 17.408
SecondaryNumber of Participants With Antiplatelet Antibodies in the Overall Population

The antiplatelet antibody was positive if optical density value \>0.129.

Time frame:
Weeks 7, 15, 23, and 24
Reported as:
Count of participants · Participants
Number of Participants With Antiplatelet Antibodies in the Overall Population
ParticipantsEfgartigimod PH20 SCPlacebo PH20 SC
Week 72010
Week 151810
Week 23179
Week 24198

Adverse events

Collected over Up to 35 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod PH20 SC1/137 (0.7%)14/137 (10.2%)130/137 (94.9%)
Placebo PH20 SC0/70 (0%)10/70 (14.3%)65/70 (92.9%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventEfgartigimod PH20 SCPlacebo PH20 SC
ThrombocytopeniaBlood and lymphatic system disorders1/1372/70
HaematuriaRenal and urinary disorders0/1372/70
COVID-19Infections and infestations3/1370/70
HeadacheNervous system disorders2/1370/70
Autoimmune thyroiditisEndocrine disorders0/1371/70
Inguinal hernia strangulatedGastrointestinal disorders0/1371/70
Arthritis infectiveInfections and infestations0/1371/70
Head injuryInjury, poisoning and procedural complications0/1371/70
Platelet count decreasedInvestigations0/1371/70
OsteonecrosisMusculoskeletal and connective tissue disorders0/1371/70
Most frequent other events
Showing 10 of 31
Most frequent other events
EventEfgartigimod PH20 SCPlacebo PH20 SC
HaematuriaRenal and urinary disorders32/13723/70
Blood urine presentInvestigations43/13720/70
EcchymosisSkin and subcutaneous tissue disorders34/13720/70
PetechiaeSkin and subcutaneous tissue disorders34/13719/70
EpistaxisRespiratory, thoracic and mediastinal disorders20/13715/70
Injection site haemorrhageGeneral disorders14/13714/70
ContusionInjury, poisoning and procedural complications22/13712/70
PurpuraSkin and subcutaneous tissue disorders15/13711/70
Gingival bleedingGastrointestinal disorders14/13710/70
Mouth haemorrhageGastrointestinal disorders19/1376/70

Baseline characteristics

Safety Analysis Set (SAF): All participants who received at least 1 dose or part of a dose.

Age, Continuous
Age, Continuous(years)Efgartigimod PH20 SCPlacebo PH20 SCTotal
Mean47.3 ± 17.2250.0 ± 15.2948.2 ± 16.60
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod PH20 SCPlacebo PH20 SCTotal
Female8843131
Male492776
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Efgartigimod PH20 SCPlacebo PH20 SCTotal
Hispanic or Latino8210
Not Hispanic or Latino12968197
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod PH20 SCPlacebo PH20 SCTotal
Asian441862
Black or African American426
White8849137
Other112
08

Study locations

200 sites
  • Investigator Site 0010116
    Springdale, Arkansas 72758, United States
  • Investigator site 0010036
    Los Angeles, California 90033, United States
  • Investigator Site 0010045
    Washington, District of Columbia 20007, United States
  • Investigator Site 0010104
    Weston, Florida 33331, United States
  • Investigator site 0010112
    Chicago, Illinois 60612, United States
  • Investigator site 0010193
    Chicago, Illinois 60637, United States
  • Investigator Site 0010079
    Lisle, Illinois 60187, United States
  • Investigator Site 0010062
    Fort Wayne, Indiana 46804, United States
  • Investigator site 0010042
    Iowa City, Iowa 52242, United States
  • Investigator Site 0010083
    Detroit, Michigan 48202, United States
  • Investigator Site 0010102
    Minneapolis, Minnesota 55455, United States
  • Investigator site 0010040
    Columbus, Ohio 43210, United States
  • Investigator Site 0010095
    Oklahoma City, Oklahoma 73142, United States
  • Investigator Site 0010115
    Pittsburgh, Pennsylvania 15222, United States
  • Investigator Site 0540001
    Buenos Aires, Argentina
  • Investigator Site 0540004
    Buenos Aires, Argentina
  • Investigator Site 0540003
    Córdoba, Argentina
  • Investigator Site 0610009
    Adelaide, Australia
  • Investigator Site 0610004
    Bedford Park, Australia
  • Investigator Site 0610002
    Box Hill, Australia
  • Investigator Site 0610010
    Clayton, Australia
  • Investigator Site 0610012
    Garran, Australia
  • Investigator Site 0610001
    Hobart, Australia
  • Investigator Site 0610011
    Perth, Australia
  • Investigator Site 0610003
    West Perth, Australia
  • Investigator Site 0610005
    Westmead, Australia
  • Investigator Site 3590017
    Plovdiv, Bulgaria
  • Investigator Site 3590015
    Sofia, Bulgaria
  • Investigator Site 0560002
    Santiago, Chile
  • Investigator Site 0560004
    Temuco, Chile
  • Investigator Site 0560003
    Viña Del Mar, Chile
  • Investigator Site 0860003
    Beijing, China
  • Investigator Site 0860013
    Beijing, China
  • Investigator Site 0860008
    Bengbu, China
  • Investigator Site 0860055
    Huizhou, China
  • Investigator Site 0860009
    Kunming, China
  • Investigator Site 0860012
    Nanchang, China
  • Investigator Site 0860014
    Shanxi, China
  • Investigator Site 0860015
    Shenzhen, China
  • Investigator Site 0860001
    Tianjin, China
  • Investigator Site 0860006
    Wenzhou, China
  • Investigator Site 0860010
    Wuhan, China
  • Investigator Site 0860002
    Wuxi, China
  • Investigator Site 0860005
    Zhejiang, China
  • Investigator Site 0860011
    Zhengzhou, China
  • Investigator Site 0860058
    Zhenjiang, China
  • Investigator site 0860062
    Zhenjiang, China
  • Investigator Site 0450005
    Roskilde, Denmark
  • Investigator Site 0330009
    Créteil, France
  • Investigator Site 0330018
    Montpellier, France
  • Investigator Site 9950006
    Tbilisi, Georgia
  • Investigator Site 9950007
    Tbilisi, Georgia
  • Investigator Site 9950008
    Tbilisi, Georgia
  • Investigator Site 9950009
    Tbilisi, Georgia
  • Investigator Site 9950011
    Tbilisi, Georgia
  • Investigator Site 9950019
    Tbilisi, Georgia
  • Investigator site 0490008
    Essen, 45147, Germany
  • Investigator Site 0490012
    Gießen, Germany
  • Investigator Site 0300008
    Athens, Greece
  • Investigator Site 0300010
    Athens, Greece
  • Investigator Site 0300007
    Patra, Greece
  • Investigator Site 0300009
    Thessaloníki, Greece
  • Investigator Site 3530002
    Dublin, Ireland
  • Investigator Site 3530003
    Dublin, Ireland
  • Investigator Site 3530001
    Galway, Ireland
  • Investigator Site 9720013
    Ashkelon, Israel
  • Investigator Site 9720010
    Haifa, Israel
  • Investigator Site 9720012
    Haifa, Israel
  • Investigator Site 9720008
    Jerusalem, Israel
  • Investigator Site 9720011
    Jerusalem, Israel
  • Investigator Site 9720007
    Petach Tikva, Israel
  • Investigator Site 9720009
    Tel Aviv, Israel
  • Investigator Site 0390037
    Alessandria, Italy
  • Investigator Site 0390043
    Ferrara, Italy
  • Investigator Site 0390045
    Meldola, Italy
  • Investigator site 0390014
    Milan, 20122, Italy
  • Investigator Site 0390032
    Milan, Italy
  • Investigator Site 0390041
    Napoli, Italy
  • Investigator Site 0390044
    Napoli, Italy
  • Investigator Site 0390015
    Novara, Italy
  • Investigator Site 0390035
    Potenza, Italy
  • Investigator Site 0390011
    Reggio Calabria, Italy
  • Investigator site 0390018
    Reggio Emilia, 42100, Italy
  • Investigator Site 0390046
    Rome, Italy
  • Investigator Site 0390033
    Terni, Italy
  • Investigator Site 0390036
    Varese, Italy
  • Investigator Site 0810056
    Chiba, Japan
  • Investigator Site 0810015
    Hirakata, Japan
  • Investigator Site 0810010
    Hiroshima, Japan
  • Investigator Site 0810053
    Kanagawa, Japan
  • Investigator Site 0810051
    Kitakyushu, Japan
  • Investigator Site 0810054
    Kumamoto, Japan
  • Investigator Site 0810018
    Maebashi, Japan
  • Investigator Site 0810057
    Morioka, Japan
  • Investigator Site 0810017
    Saitama, Japan
  • Investigator Site 0810016
    Shibukawa, Japan
  • Investigator Site 0810023
    Shimotsuke, Japan
  • Investigator Site 0810039
    Shinagawa-Ku, Japan
  • Investigator Site 0810038
    Tama, Japan
  • Investigator Site 0810052
    Tokyo, Japan

Showing the first 100 of 200 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Oct 2023, 33 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 33 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2020
First posted
Dec 29, 2020
StartActual
Dec 16, 2020
Primary completionActual
Oct 9, 2023
CompletionActual
Oct 9, 2023
Results first posted
Oct 31, 2024
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04687072
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Dec 29, 2020
Start date
Dec 16, 2020
Primary completion
Oct 9, 2023
Completion
Oct 9, 2023
Results posted
Oct 31, 2024
Last update
Oct 31, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion